CREATE Medicines to Host Investor and Partnering Meetings at the 2026 Jefferies Global Healthcare Conference in London

On November 6, 2026 CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo multi-immune programming, reported that members of its senior management team will host one-on-one meetings with investors and prospective partners at the Jefferies Global Healthcare Conference in London, taking place from November 16–19, 2026, at the Waldorf Hilton and ME London. CREATE will be represented by Daniel Getts, PhD, CEO and Co-Founder, and Matthew Maurer, MD, Chief Medical Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CREATE is a leader in in vivo CAR therapy, with over 80 patients treated, the largest clinical dataset in the field. The company’s proprietary platform selectively programs immune cells directly inside the body for either transient or stable CAR expression, all from RNA. CREATE’s clinical-stage programs include:

CRT-402, a CD19-targeted in vivo CAR
MT-303, a GPC3-targeted in vivo CAR
MT-302, a TROP2-targeted in vivo CAR
MT-304, a HER2-targeted in vivo CAR
Investors who wish to request a meeting should contact their Jefferies representative. Prospective partners may contact [email protected].

(Press release, Create Medicines, NOV 6, 2026, View Source [SID1234674410])

CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates

On November 6, 2026 CG Oncology, Inc. (NASDAQ: CGON) reported financial results for the third quarter ended September 30, 2026, and provided business updates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are entering an eventful period for CG Oncology as we look forward to sharing PIVOT-006 topline data this month. As a reminder, PIVOT-006 is the first randomized registrational trial in intermediate-risk and high-grade Ta NMIBC. Additionally, we expect to have 12-month data from both CORE-008 Cohort CX and BOND-003 Cohort P in December, which further strengthens the growing body of evidence for cretostimogene across the NMIBC landscape and supports our goal to address the broadest number of patients. We remain confident in cretostimogene’s potential to become a backbone therapy for patients and to create long-term value for shareholders," stated Arthur Kuan, Chairman, President & Chief Executive Officer at CG Oncology.

Corporate Highlights

Strengthened Executive Leadership Team with the addition of life-science executive Isabel Kalofonos as Chief Commercial Officer
In October, the Company appointed Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos brings more than 20 years of experience driving successful launches including PALSONIFYTM (paltusotine) and ELAHERE (mirvetuximab soravtansine) through strong commercial execution, helping bring innovative therapies to patients at scale across the biotechnology and pharmaceutical industries.
Anticipated 2026 Milestones

PIVOT-006 (intermediate-risk and high-grade Ta ≤ 3cm NMIBC): Phase 3 topline data November 2026
CORE-008 Cohort CX (BCG-exposed HR and BCG-unresponsive NMIBC) 12-month data December 2026
BOND-003 Cohort P (BCG-unresponsive papillary only NMIBC) 12-month data December 2026
Completion of BLA submission in initial indication of BCG-unresponsive NMIBC with CIS with or without papillary disease Q4 2026

Third Quarter Financial Highlights

Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2026 were $984.5 million, compared with $1.0 billion as of June 30, 2026.  The Company anticipates its existing cash, cash equivalents and marketable securities as of this date will be sufficient to fund operations through 2029.
Research and Development (R&D) Expenses: R&D expenses were $39.2 million for the third quarter of 2026, as compared to $27.9 million for the prior year period. The increase was primarily due to an increase in clinical trial expenses, including CMC costs, and an increase in compensation costs due to increased headcount.
General and Administrative (G&A) Expenses: G&A expenses were $23.0 million for the third quarter of 2026, as compared to $23.3 million for the prior year period. The decrease was primarily due to a decrease in professional and consultant fees, partially offset by an increase in personnel-related expenses, including compensation costs from increased headcount, and an increase in other general G&A expenses.
Net Loss: Net loss was $56.9 million, or $(0.64) per share, for the third quarter of 2026, as compared to a net loss of $43.8 million, or $(0.57) per share, for the prior year period.

About Cretostimogene Grenadenorepvec

Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 700 patients with Non-Muscle Invasive Bladder Cancer (NMIBC). This program includes two Phase 3 clinical trials: BOND-003 for BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk and high-grade Ta ≤ 3cm NMIBC. Cretostimogene has received FDA Fast Track and Breakthrough Therapy designations for BCG-unresponsive NMIBC. CG Oncology also has a multi-cohort trial, CORE-008, evaluating the safety and efficacy of cretostimogene in BCG-exposed HR and BCG-unresponsive NMIBC. Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet certain program eligibility requirements. Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority.

(Press release, CG Oncology, NOV 6, 2026, View Source [SID1234674426])

MaaT Pharma Provides an Update on Preliminary Findings from the Investigator-Sponsored Phase 2a PICASSO Trial in Metastatic Melanoma

On November 6, 2026 MaaT Pharma (EURONEXT: MAAT – the "Company"), a late-stage clinical biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, reported an update on the preliminary findings from the Phase 2a PICASSO clinical trial, an investigator-sponsored study conducted by AP-HP in collaboration with INRAe and Gustave Roussy evaluating MaaT013 (Xervyteg) in combination with immune checkpoint inhibitors (ipilimumab and nivolumab) in patients with advanced, unresectable or metastatic melanoma who had not previously received anti-CTLA-4, anti-PD-1 or anti-PD-L1 therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This communication follows the publication of study information in the EU Clinical Trials Information System (CTIS), as submitted by the PICASSO investigators. The findings reported here are derived exclusively from this CTIS disclosure and should not be considered a final scientific publication of the study results. Full results and analyses will be presented by the PICASSO investigators at a future scientific congress. Preliminary results are available here in CTIS.

Preliminary findings, based on currently available data extracted from the CTIS submission:

The study met its primary objective of assessing the safety and feasibility of adding MaaT013 (Xervyteg) to ipilimumab and nivolumab in treatment-naïve metastatic melanoma. No statistically significant difference was observed in the incidence of Grade 3 or higher adverse events between the two treatment arms.
Based on the currently available data, the safety profile observed with MaaT013 (Xervyteg) in combination with ipilimumab and nivolumab was generally consistent with the expected safety profile of the immunotherapy combination.
Response rates, a main secondary endpoint, were comparable in the MaaT013 (Xervyteg) and placebo arms and consistent with previously reported response rates for ipilimumab and nivolumab combination therapy.
Additional secondary endpoints were also assessed, including longitudinal microbiome and biomarker analyses.
Exploratory analyses suggest that baseline microbiome composition (i.e.: before treatment) may influence clinical response to MaaT013 (Xervyteg), warranting further investigation.
Treatment with MaaT013 (Xervyteg) was associated with significant increases in microbiome richness and diversity compared to placebo, confirming an effect of MaaT013 (Xervyteg).

"PICASSO provides important safety and feasibility-controlled data on the administration of a microbiome therapy in combination with immune checkpoint inhibitors," said Hervé Affagard, Chief Executive Officer and co-founder of MaaT Pharma. "These findings provide further insight into the importance of treatment setting and patient selection. Together with the planned microbiome analyses, they will help inform the immuno-oncology strategy as we continue to advance MaaT034 development in ICI-refractory patients."

A total of 70 patients were randomized across five centers in France. The analysis included 69 patients, with 34 patients in the MaaT013 (Xervyteg) arm and 35 patients in the placebo arm. The Company provided MaaT013 (Xervyteg) and placebo and generated shotgun metagenomic profiles of patients using its proprietary gutPrint research engine. The PICASSO trial (ClinicalTrials.gov: NCT04988841 and CTIS / EU Clinical Trial (EU CT) number: 2024-516100-42-00) is fully funded by the Directorate of Health Care Supply (DGOS: Direction Générale de l’Offre de Soins) and operated by the French National Cancer Institute (INCa: Institut National du Cancer) as part of a call for projects (project PHRC-K19-183).

(Press release, MaaT Pharma, NOV 6, 2026, View Source [SID1234674393])

VS Pharmtech Boosts Cancer Treatment Efficacy Without Adding Toxicity

On November 6, 2026 VS Pharmtech reported that cancer drugs keep improving, but their limits remain. When antibody therapies first emerged, only a fraction of patients benefited, and small-molecule anticancer drugs often carry severe toxicity. Rather than developing a new anticancer drug, Park Shin-young, CEO of VS Pharmtech (View Source), has focused on an "anticancer efficacy enhancer" that strengthens existing treatments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Park graduated from Seoul National University’s School of Applied Biology and Chemistry. He then worked in planning roles at Daewon Pharmaceutical, SCM Lifescience and CLIPS, a clinical research company. "Whether a new drug can be commercialized is decided in the clinic," Park said. "I was drawn to the fact that you can gauge a drug’s chances of success early, at the clinical stage."

The company grew out of a patent advisory meeting at the Korea Institute of Radiological & Medical Sciences in late 2018. There, Park encountered research on combining an existing drug with radiation therapy to improve its anticancer effect. He suggested that developing the approach into an efficacy enhancer could give it much wider use. He was offered the chance to start a company on the spot and founded VS Pharmtech that November.

A 20-year-old drug at one-fifth the dose

The company’s lead pipeline candidate, VS-101, is a radiosensitizer that makes tumors more responsive to radiation so that more cancer cells die. When radiation damages a cancer cell’s DNA, the cell detects the damage and tries to repair it. VS-101 weakens RAD51, a protein central to that repair process, and drives the cancer cell toward death.

VS-101 is being developed through drug repositioning, which finds new uses for an existing medicine. In this case, the drug has been used for more than 20 years. The company aims to give patients only about 20% of the original dose. "The drug itself doesn’t cause DNA damage or toxicity," Park said. "We designed the dose so that patients receiving other cancer treatments can take it alongside them without strain."

The first results came from a Phase 1 trial in Korea. Seven patients with stage 1–3 head and neck cancer received VS-101 together with radiation therapy. All seven achieved complete remission, meaning their tumors disappeared, with no dose-limiting toxicities or serious adverse events.

Based on these results, the U.S. Food and Drug Administration (FDA) approved the company’s Phase 2 plans for head and neck cancer, breast cancer and glioblastoma. These trials extend to patients receiving chemotherapy and radiation together, adding VS-101 to cisplatin for head and neck cancer and to temozolomide for glioblastoma. "This means the FDA recognized that VS-101 causes no significant harm when combined with other anticancer drugs," Park said. "We expect approval for a trial in hard-to-treat ovarian cancer, in combination with a PARP inhibitor, in the first half of next year." The current trials, run at U.S. institutions including Yale Cancer Center, add VS-101 to standard chemoradiation for patients with advanced head and neck cancer. The goal is to improve outcomes without additional side effects.

Seeking joint research at Berkeley

VS Pharmtech is pursuing commercialization on two tracks. For VS-101, it plans to discuss global licensing deals based on interim Phase 2 data. For its preclinical candidates, which are covered by new-compound patents, it is negotiating region by region. One option is to supply them as payloads to antibody-drug conjugate (ADC) developers. The company is in talks with firms in the Middle East, Latin America, Japan and China.

The company is also expanding its overseas footprint. It was selected for MARU SF, run by the Asan Nanum Foundation, and then for Bakar Labs, an accelerator program at UC Berkeley. VS Pharmtech is the first Korean company admitted to Bakar Labs. "The first resident company we reached out to was Catena Biosciences, founded by former students of Professor Jennifer Doudna, the 2020 Nobel laureate in chemistry," Park said. "We plan to actively pursue joint R&D with member companies."

Going abroad has not been without difficulties. "Getting FDA approval for a Phase 2 trial doesn’t cost much, but it serves as official recognition that you can run clinical development overseas," Park said. "I hope there will be more government programs, training and patent support that let companies practice this process in advance."

VS Pharmtech has raised a cumulative KRW 18.6 billion (about US$13 million) and is currently raising additional funding. It aims to list on the KOSDAQ in 2027 and has already appointed a lead underwriter to plan its timeline. "The timing of the listing will depend on when we close a licensing deal and how large it is," Park said. "We hope to share good news soon."

The company is also a resident of SVC Seoul, a global startup hub in Seoul’s Hongdae area. The hub was established to connect startups with strong overseas growth potential to companies, universities, and investors in Korea and abroad.

(Press release, VSPharmTech, NOV 6, 2026, View Source [SID1234674411])

Azalea Therapeutics Presents New Preclinical Data at SITC 2026 Highlighting Durable Anti-Tumor Activity and Modular Capabilities of its In Vivo CAR T Cell Platform

On November 6, 2026 Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, reported new preclinical data demonstrating durable anti-tumor activity and the versatility of its proprietary in vivo TRAC-CAR T cell platform. The findings, to be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting (SITC 2026), taking place November 4 – 8, 2026, in Phoenix, Arizona, highlight the platform’s ability to generate functional CAR T cells through precise genomic integration, achieve durable tumor control across hematologic and solid tumor models and enable advanced engineering strategies designed to address key limitations of conventional CAR T cell therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Azalea’s proprietary dual-vector platform combines T cell-targeted enveloped delivery vehicles (EDVs) delivering transient CRISPR-Cas9 complexes with T cell-tropic adeno-associated viruses (AAVs) carrying a promoterless CAR gene. This approach enables precise insertion of the CAR gene at the TRAC locus, placing CAR expression under control of the endogenous T cell promoter. The platform is designed to generate potent, durable and physiologically regulated CAR T cells directly inside the body, without the need for individualized ex vivo manufacturing.

"These data reinforce both the potency and versatility of our precision in vivo CAR T platform," said Jenny Hamilton, Ph.D., co-founder, president and chief executive officer of Azalea Therapeutics. "Beyond generating functional CAR T cells directly in the body, we are demonstrating the ability to engineer increasingly sophisticated CAR designs that address important challenges in cell therapy, including antigen escape, solid tumor activity and long-term disease control. Combined with our previously reported non-human primate findings, these results strengthen our confidence in the platform’s potential to deliver a new generation of more accessible and durable cell therapies."

Key Findings from the SITC (Free SITC Whitepaper) Presentation

The presentation highlights new preclinical data demonstrating:

Durable leukemia tumor clearance, including following rechallenge
A single intravenous administration of EDV and AAV generated TRAC-CAR T cells in humanized mouse models, resulting in dose-dependent CAR T cell generation and complete clearance of CD19-positive NALM6 leukemia at active dose levels. In select treatment groups, tumor control was maintained following a secondary tumor challenge approximately 60 days after initial treatment, without additional dosing, supporting the potential for durable anti-tumor activity.
Dual-antigen targeting to address tumor escape
The modular platform enabled in vivo generation of dual CD19/CD20-targeted TRAC-CAR T cells, demonstrating activity against antigen-heterogeneous leukemia cells and supporting the potential to limit antigen escape, an important mechanism of resistance to CAR T cell therapy.
Enhanced solid tumor activity through CAR armoring
In a humanized mouse model of mesothelin-expressing solid tumors, in vivo-engineered TRAC-CAR T cells demonstrated strong anti-tumor activity, with co-delivery of performance-enhancing peptides (PEPs) further improving tumor control. These findings support the platform’s ability to incorporate additional functional elements to enhance CAR T cell activity in challenging tumor settings.
Precise genomic integration
Genome-wide integration-site analysis in human splenocytes from humanized mice showed that 99% of sequencing reads passing filtering mapped to the intended TRAC locus, supporting the genomic locus-specific integration capabilities of the platform.
Robust pharmacodynamic activity in non-human primates
Consistent with previously reported results, a single intravenous administration generated TRAC-CAR T cells in immunocompetent non-human primates, with CAR T cells reaching up to 41% of peripheral T cells and deep B cell depletion observed across peripheral blood, lymph nodes and bone marrow without prior lymphodepletion.
"One of the key advantages of our approach is the ability to combine cell-selective delivery with precise, programmable genomic integration," said Connor Tsuchida, Ph.D., scientific co-founder and vice president of research and development at Azalea Therapeutics. "The durable tumor control following rechallenge, along with our ability to engineer dual-targeting and armored CAR T cells, demonstrates the flexibility of this platform to address diverse therapeutic challenges even beyond hematologic malignancies. Importantly, the activity observed across mouse and non-human primate models provides further support for advancing this technology toward clinical translation."

Azalea will present these data at the SITC (Free SITC Whitepaper) 2026 Annual Meeting.

Abstract Number: 950
Title: In vivo TRAC-CAR T cell engineering via cell-selective delivery and genomic locus-specific integration results in potent tumor clearance in mice and B cell depletion in non-human primates
Presenting Author: Connor Tsuchida, Ph.D., Azalea Therapeutics
Presentation Date: Saturday, November 7, 2026
Poster Presentation Times: 12:15 – 1:45 pm and 6:45 – 8:10 pm MST
Location: Phoenix Convention Center

The ePoster will be available on the SITC (Free SITC Whitepaper) virtual meeting platform beginning Friday, November 6, 2026, at 9:00 am ET.

(Press release, Azalea Therapeutics, NOV 6, 2026, View Source [SID1234674427])